|
Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer Clinical research trials and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer. Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer clinical trial. Subjects typically recieve the finest healthcare available for their Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer  Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
For Condition: stage 4 renal cell cancer,recurrent renal cell cancer,renal clear cell carcinoma
Status: Recruiting
Sponsor(s): Fox Chase Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill cancer cells. Sometimes the transplanted cells can be rejected by the body's tissues. Mycophenolate mofetil, tacrolimus, and donor white blood cells may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by peripheral stem cell transplantation in treating patients who have metastatic or recurrentkidney cancer.
Details: OBJECTIVES: - Determine the feasibility of submyeloablative HLA-identical allogeneic peripheral blood stem cell transplantation in patients with metastatic or recurrent renal cell carcinoma. - Determine the toxicity of this regimen, in terms of incidence and severity of graft rejection, acute graft-vs-host disease (GVHD), chronic GVHD, adverse effects from the preparative regimen and thalidomide, and infection and bleeding, in these patients. - Determine the efficacy of this regimen, in terms of objective partial and complete response rates, in these patients. - Determine the engraftment rates and extent of chimerism in patients treated with this regimen. - Determine the overall survival and time to treatment failure rate in patients treated with this regimen. - Determine the impact of thalidomide on the treatment of chronic GVHD in patients treated with this regimen. OUTLINE: Patients are stratified according to risk (low vs high). Patients receive fludarabine IV over 30 minutes once daily on days -4 to -2 followed by total body irradiation on day -1. Patients receive tacrolimus IV over 24 hours or orally daily on days -3 to 35 and oral mycophenolate mofetil twice daily on days -3 to 28 as graft-vs-host disease (GVHD) prophylaxis. Patients undergo allogeneic peripheral blood stem cell transplantation over 1-2 hours on day 0. Patients maintaining a mixed chimerism with no evidence of grade III or IV GVHD receive donor lymphocyte infusions (DLI) on days 60, 90, and 120. Patients may receive additional DLI as needed. Patients with limited chronic GVHD receive oral thalidomide daily beginning after day 80 and continuing for 1 year or until disease progression or resolution of chronic GVHD. Patients are followed at 1, 3, 6, and 12 months and then every 6 months thereafter. PROJECTED ACCRUAL: A maximum of 20-40 patients (10-20 per stratum) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed renal cell carcinoma (RCC) - Histology demonstrates major clear cell component - Metastatic (stage IV) or recurrent disease - Prior debulking nephrectomy required - Disease not amenable to complete surgical resection - Must have HLA-identical donor - Matched related sibling donors must have 6/6 serologic HLA A, B, and DR match with molecular confirmation at DRB1 - A 5/6 serologic mismatch with one antigen mismatch at locus A or B (not DR) with molecular confirmation at locus A, B, and DRB1 allowed - Matched unrelated donors must have a minimum of 8 out of 10 molecular matches at loci A, B, C, DRB1, and DQB1 - No brain metastases - Negative MRI required PATIENT CHARACTERISTICS: Age: - 18 to 65 Performance status: - Karnofsky 80-100% OR - ECOG 0-1 Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Bilirubin less than 2 times upper limit of normal (ULN) - ALT/AST less than 2 times ULN - Alkaline phosphatase less than 2 times ULN - Hepatitis A, B, and C negative Renal: - Creatinine clearance greater than 50 mL/min - Calcium less than 10.5 mg/dL (bisphosphonates allowed) Cardiovascular: - LVEF no less than 10% below lower limit of normal Pulmonary: - FEV_1 and DLCO greater than 50% Other: - HIV negative - No active bacterial, fungal, or viral (including cytomegalovirus) infections - No intolerance or allergy to tacrolimus, mycophenolate mofetil, or fludarabine - No intolerance to 200 cGy of total body irradiation - No other serious comorbid disease, neurologic condition, or psychosocial condition that would preclude study follow-up - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception for at least 1 month before, during, and for at least 3 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: - Prior interleukin-2 allowed - Prior interferon alfa allowed Chemotherapy: - Prior chemotherapy allowed - No other concurrent chemotherapy for RCC Endocrine therapy: - No concurrent corticosteroids for other comorbid disease Radiotherapy: - No prior extensive radiotherapy to marrow microenvironment greater than 20% of total marrow mass - No prior radiotherapy that has reached tissue tolerance for heart, lung, liver, kidney, or spinal cord Surgery: - See Disease Characteristics Other: - No other concurrent therapy for RCC - No concurrent enrollment on another investigational protocol for treatment of RCC - No other concurrent immunosuppressive medications - No other concurrent investigational drugs
Total Enrollment:
Location and Contact Information:
Overall Study Official:
KennethMangan, Study Chair, Fox Chase Cancer Center
Fox Chase - Temple Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19111-2442
United States
Recruiting Kenneth Mangan 215-214-3129
Fox Chase Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19111-2497
United States
Recruiting Gary Hudes 215-728-2984
Additional Information:
Study ID Numbers: CDR0000068970; NCI-G01-2021,TUHSC-3721,FCCC-01006
Study Start Date:
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00025519
Other Recurrent Renal Cell Cancer Studies:
1. Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
2. Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
3. Epothilone B in Treating Patients With Advanced Kidney Cancer
4. SU011248 in Treating Patients With Cytokine-Refractory Metastatic Renal Cell Cancer
5. Erlotinib in Treating Patients With Advanced Kidney Cancer
Related Studies:
Other recurrent renal cell cancer Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
|
|
|
|
|
|
|
|
